Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Professional collection · English
Collection mapClinical judgment

Stem Cells & Perinatal Therapies · Professional series · EN

Safety, uncertainty, and follow-up: compare the right risks

Neither “natural” nor “experimental” is a complete risk assessment.

By Olga Goodman, MD · Evidence through 25 September 2026

On this page
  1. Avoid both reassurance by slogan and fear by association
  2. Separate categories of risk
  3. The route changes the safety question
  4. Individual factors to review
  5. An event is not automatically a treatment effect
  6. What a follow-up plan should specify
  7. The central principle

Avoid both reassurance by slogan and fear by association

Autologous origin does not eliminate procedural or processing risks. Donor origin does not make a treatment uniformly unsafe. A severe complication reported with one uncontrolled product or unusual route should not be converted into the expected risk of every MSC trial. The converse is also true: a small study with no treatment-attributed serious events cannot establish universal safety. R05 R07

The correct unit of evaluation is the defined intervention and context.

Separate categories of risk

For consultation, it helps to distinguish product-related risks, administration-related risks, disease-related risks, and risks arising from delay or displacement of other care. Product issues may involve contamination, identity, composition, or consistency. Administration issues depend on route and setting. Disease-related assessment depends on the individual’s medical situation. Opportunity cost includes financial burden and time lost from a more appropriate evaluation.

This is a practical classification, not a numerical risk calculator. It helps keep a discussion complete without pretending that all categories have the same probability or severity.

The route changes the safety question

An intra-articular procedure, an intravenous infusion, a skin injection, a surgical graft, and an intrathecal or ocular intervention are different procedures. Safety information from one route is not a substitute for safety information from another. When a provider cites a favorable safety profile, ask whether the cited study used the same route and formulation. R05

The same caution applies to cell types. Risks associated with intensive hematopoietic transplantation or with pluripotent-cell-derived products should not simply be assigned to an MSC preparation. Each requires its own analysis. R07 R09

Individual factors to review

A proposed intervention may require assessment of active infection, malignancy history, clotting history, organ function, immune suppression, pregnancy or reproductive plans, prior reactions, and the medications currently being used. These are review domains, not a universal contraindication list. A competent team should explain which factors actually change eligibility or monitoring for the particular product.

Do not independently stop prescribed treatment to make room for an infusion. Medication management must be coordinated with the clinicians responsible for the underlying disease and, when applicable, the research protocol.

An event is not automatically a treatment effect

When reading follow-up data, distinguish an adverse event that occurred during observation from an event judged to be caused by treatment. Both should be reported; neither should be silently discarded or misrepresented. Small uncontrolled cohorts may be unable to resolve causality or detect uncommon harms. The 2026 RA follow-up illustrates why actual event tables and attribution matter more than a generalized reassurance statement. R10

What a follow-up plan should specify

Before treatment, identify who receives urgent calls, where complications will be evaluated, who has access to the product and lot information, how later events will be recorded, and how communication with the treating specialist will occur. The plan should survive the patient’s return home from another city or country.

Clinical deterioration after a procedure should not be dismissed as a required “healing response” without appropriate evaluation. Severe symptoms such as breathing difficulty, chest pain, fainting, new neurologic symptoms, or a rapidly worsening painful swollen joint require urgent medical assessment; a website or routine portal message is not the appropriate pathway.

The central principle

Good safety practice does not oppose innovation. It makes the result of innovation interpretable and protects the people whose trust allows the field to develop.

Sources

R05. FDA. Important Patient and Consumer Information About Regenerative Medicine Therapies. 2021.

https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies

Historical consumer safety guidance. Its older statement about the only approved stem-cell products must NOT substitute for the current FDA register. Access: Official FDA consumer page.

R07. ISSCR. Guidelines for Stem Cell Research and Clinical Translation: Clinical Translation of Stem Cell-Based Interventions.

https://www.isscr.org/guidelines-online/clinical-translation-of-stem-cell-based-interventions

Primary professional framework for translation, manufacturing, research oversight, and informed consent. Access: Online primary guidelines.

R09. Alexander T, et al. Autologous haematopoietic stem cell transplantation for rheumatic diseases: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee. Bone Marrow Transplant. 2025;60:1451–1464. doi:10.1038/s41409-025-02695-y.

https://www.nature.com/articles/s41409-025-02695-y

Published August 20, 2025. Center selection and multidisciplinary recommendations; underlying literature search through September 2024. Access: Publisher full text.

R10. Park EH, et al. Long-term safety of intravenous human umbilical cord blood-derived mesenchymal stem cell therapy in rheumatoid arthritis: a 5-year follow-up study. Stem Cells Transl Med. 2026;15(8):szag062. doi:10.1093/stcltm/szag062.

https://academic.oup.com/stcltm/article/15/8/szag062/8752872

Published August 5, 2026. Nine-patient observational follow-up; full results read, not just the optimistic significance statement. Access: Publisher full text.

Olga Goodman, MD · Rheumatology in Perspective · A RheumaView publication

Educational publication; not individualized medical advice or procedure clearance. No dosing protocol is provided. This is a selective, dated review rather than an exhaustive systematic review.

Original text requires author and source attribution. Do not submit personal medical information in public comments.

Back to top

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: adverse eventsfollow-upinfectionmedical tourismrisksafety